Prostamax is a synthetic short peptide from the Khavinson “bioregulator” family, marketed for prostate-tissue support. It is one of the least-documented compounds in this product line in the Western scientific literature: no PubMed-indexed study specifically on “Prostamax” or a confirmed prostate-specific peptide sequence under this name was identified in this review. Vendor sources disagree on the exact amino-acid sequence. It is not an approved drug anywhere, and independent verification of its claimed mechanism is essentially absent.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed for prostate-tissue support |
| Primary research interest | Prostate-tissue support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — no PubMed-indexed study specifically on “Prostamax” or a confirmed prostate-specific peptide sequence under this name was identified |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold as an oral capsule or reconstituted research powder |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Prostamax |
| Alternative names | Marketed as part of the Khavinson “Cytomax”/bioregulator peptide line |
| Peptide sequence | Not reliably established — vendor sources disagree on the exact amino-acid sequence, and no PubMed-indexed study confirming a “Prostamax” compound was identified |
| Amino-acid length | Not reliably established |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator”/”Cytomax” peptide line (Saint Petersburg Institute of Bioregulation and Gerontology) |
| Primary biological target | Not established — no PubMed-indexed primary research located for this named compound |
| Developer or originator | Saint Petersburg Institute of Bioregulation and Gerontology (Khavinson group), for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Prostamax is marketed as part of the Khavinson-group “Cytomax”/bioregulator peptide line developed at the Saint Petersburg Institute of Bioregulation and Gerontology, following the same organ-specific naming pattern as other entries in this family (e.g., a cardiac peptide, a vascular peptide, a thymic peptide). It is sold as an oral capsule or reconstituted research powder and marketed specifically for prostate gland health and aging.
Unlike some of its sister compounds (notably Vilon and Vesugen, which have several PubMed-indexed cell-culture studies), no PubMed-indexed primary research study using the name “Prostamax,” and no confirmed prostate-tissue-specific peptide study from the Khavinson group under any sequence, was identified in this review. Vendor educational pages for Prostamax cite general Khavinson-program references (broad books and reviews on “genome peptide regulation,” general gerontology, and cancer-related peptide reviews) rather than a study specific to prostate tissue or this named compound, and vendor pages themselves acknowledge that literature “originates almost entirely from one research programme.” This makes Prostamax one of the more speculative entries in this peptide family.
How does it work?
Plain-English explanation
The general theory behind this whole peptide family is that very short peptides can help nudge aging cells in a specific organ back toward a more youthful pattern of gene activity. For Prostamax, this idea has not been directly tested and confirmed in a peer-reviewed, prostate-specific study identified in this review — the mechanism is inferred from the broader Khavinson bioregulator concept rather than demonstrated for this compound.
Technical explanation
No prostate-tissue-specific mechanistic data (gene-expression changes in prostate epithelial or stromal cells, effects in benign prostatic hyperplasia or prostate cancer models) attributable specifically to a compound reliably identified as Prostamax were located in PubMed during this review. General Khavinson-group mechanistic work on other short peptides (AED, KED, KE, AEDG, EDR) in unrelated cell types has been published and is described in this site’s other bioregulator entries, but extrapolating those unrelated findings to a prostate-specific claim for Prostamax would not be scientifically sound, and this entry does not do so.
Potential benefits and research applications
Prostate tissue and cellular aging (as marketed)
What is being investigated: vendor marketing describes Prostamax as supporting prostate cellular aging, tissue maintenance, and general prostate health. How the effect might occur: not established — no compound-specific mechanistic study was identified. Evidence: none identified specific to Prostamax or confirmed prostate tissue research in PubMed during this review. Strength: has not been established. This should be read as a marketing claim built on the general Khavinson bioregulator narrative, not as a tested finding.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified. No human clinical trial of Prostamax was located.
Amounts studied in animal research
No established or reliably sourced dosing information was identified. No confirmed, compound-specific animal dosing study was located.
Practitioner and community-reported protocols
Vendor pages selling Prostamax as a 20 mg lyophilized vial describe generic rodent-study dosing in the “microgram per kilogram” range and describe an unspecified “Russian clinical record” as involving “ten to twenty day courses at amounts in the tens to low hundreds of micrograms,” without naming a specific trial, journal, or year that could be checked. This figure is widely repeated online, but its original source could not be verified, and no vendor page reviewed provided a checkable citation for it.
Explanation of the reported figures
Prostamax dosing claims found during this review were vaguer and less specific than for other compounds in this family — vendor pages describe general ranges (“tens to low hundreds of micrograms,” “ten to twenty day courses”) attributed only to an unnamed “Russian clinical record” rather than a specific, checkable study. No PubMed-indexed source could be found to confirm, refute, or add detail to these figures. This is a case where the honest conclusion is that essentially nothing about Prostamax dosing has been independently verified — what circulates is vendor-generated language modeled on the general Khavinson bioregulator dosing pattern (short oral courses, microgram-to-low-milligram range) rather than a documented compound-specific finding.
What circulates E5
Vendor pages selling Prostamax describe vague dosing language — generally rodent studies in the "microgram per kilogram" range and an unnamed "Russian clinical record" describing "ten to twenty day courses at amounts in the tens to low hundreds of micrograms" — without citing a specific, checkable study. Widely repeated online, but its original source could not be verified. No specific milligram figure, frequency, or route could be confirmed as tracing to any identifiable published source, human or animal. This should be treated as vendor-tier marketing language, not as documented dosing evidence.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No human or confirmed animal study exists to characterize side effects for this compound specifically. As with other unregulated peptide products, purity, accurate labeling, contamination, correct concentration, and sterility are not guaranteed for vendor-sold Prostamax. Essentially nothing about its safety, appropriate dose, or interactions has been independently established.
Regulatory and developmental status
Prostamax has no drug approval in the United States, European Union, or Russia identified in this review. It is sold as an oral “bioregulator” supplement and research chemical, not as a registered pharmaceutical, and has not entered any recognized clinical trial pipeline identified in this review. Status verified as of the date below.
Frequently asked questions
What is Prostamax?
A marketed Khavinson-family “bioregulator” peptide positioned for prostate support; its specific amino-acid sequence and any dedicated prostate-tissue study could not be confirmed in this review.
What is the sequence of Prostamax?
Not reliably established. Different vendor sources give different sequences for this compound, and no peer-reviewed source confirming a specific sequence under the name Prostamax was identified.
Has Prostamax been studied in humans?
No established or reliably sourced human clinical study was identified.
What dosage circulates online?
Vendors describe vague ranges (tens to low hundreds of micrograms over 10-20 days) attributed to an unnamed “Russian clinical record.” Widely repeated online, but its original source could not be verified.
Is Prostamax approved anywhere?
No. It is not an approved medicine in any jurisdiction identified in this review.
What remains unknown?
Essentially everything specific to this compound: its confirmed sequence, any dedicated prostate-tissue mechanistic or animal study, and any verifiable human dosing figure.
Bottom line
Prostamax is among the least independently documented compounds in the Khavinson bioregulator family. No PubMed-indexed, compound-specific study was identified during this review, vendor sources disagree on its sequence, and the dosing figures that circulate are vague and attributed only to an unnamed source. It should be treated as a marketed research/supplement product built on the general Khavinson bioregulator narrative rather than as a peptide with its own demonstrated evidence base.